Cargando…
Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos
INTRODUCTION. Type 1 narcolepsy is a disabling disease that requires continuous treatment, which is not always effective. Pitolisant is a new drug with a different mechanism of action that offers a new treatment option. The objective of the study was to analyse the effectiveness and safety of pitoli...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Viguera Editores (Evidenze Group)
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280761/ https://www.ncbi.nlm.nih.gov/pubmed/36169322 http://dx.doi.org/10.33588/rn.7507.2022090 |
_version_ | 1785060869812518912 |
---|---|
author | del Río-Villegas, Rafael Martínez-Orozco, Francisco J. Tomás, Odile Romero-Santo Cortés, María Yébenes Gómez-Barrera, Manuel Gaig-Ventura, Carles |
author_facet | del Río-Villegas, Rafael Martínez-Orozco, Francisco J. Tomás, Odile Romero-Santo Cortés, María Yébenes Gómez-Barrera, Manuel Gaig-Ventura, Carles |
author_sort | del Río-Villegas, Rafael |
collection | PubMed |
description | INTRODUCTION. Type 1 narcolepsy is a disabling disease that requires continuous treatment, which is not always effective. Pitolisant is a new drug with a different mechanism of action that offers a new treatment option. The objective of the study was to analyse the effectiveness and safety of pitolisant in patients with type 1 narcolepsy that did not respond to or tolerate previous standard treatments. PATIENTS AND METHODS. Real-life multicentre descriptive observational study that included patients diagnosed with type 1 narcolepsy who did not respond to or tolerate previous treatments and started treatment with pitolisant. The study evaluated three different moments: the start of treatment, the stabilization of treatment with pitolisant and the three months after. RESULTS. In 32 patients included (mean age, 44 years; 37.5% women) the mean of the Epworth Sleepiness Scale was reduced from 17.1 to 13.5; 47.8% of the patients improved from their cataplexy; 65% of the patients improved their clinical global impression at the physician’s and at the patient’s discretion and the mean number of medications consumed was reduced from 2.0 to 1.4. The most frequent adverse effect was insomnia in 21.9% of patients. Of the 32 patients, 23 continued with the treatment during the 3-month follow-up period. CONCLUSIONS. In patients with type I narcolepsy who do not respond to or do not tolerate the available treatments, pitolisant can improve their clinical situation and reduce their medication consumption. Studies with a higher level of evidence are needed to confirm these results. |
format | Online Article Text |
id | pubmed-10280761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Viguera Editores (Evidenze Group) |
record_format | MEDLINE/PubMed |
spelling | pubmed-102807612023-06-21 Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos del Río-Villegas, Rafael Martínez-Orozco, Francisco J. Tomás, Odile Romero-Santo Cortés, María Yébenes Gómez-Barrera, Manuel Gaig-Ventura, Carles Rev Neurol Original INTRODUCTION. Type 1 narcolepsy is a disabling disease that requires continuous treatment, which is not always effective. Pitolisant is a new drug with a different mechanism of action that offers a new treatment option. The objective of the study was to analyse the effectiveness and safety of pitolisant in patients with type 1 narcolepsy that did not respond to or tolerate previous standard treatments. PATIENTS AND METHODS. Real-life multicentre descriptive observational study that included patients diagnosed with type 1 narcolepsy who did not respond to or tolerate previous treatments and started treatment with pitolisant. The study evaluated three different moments: the start of treatment, the stabilization of treatment with pitolisant and the three months after. RESULTS. In 32 patients included (mean age, 44 years; 37.5% women) the mean of the Epworth Sleepiness Scale was reduced from 17.1 to 13.5; 47.8% of the patients improved from their cataplexy; 65% of the patients improved their clinical global impression at the physician’s and at the patient’s discretion and the mean number of medications consumed was reduced from 2.0 to 1.4. The most frequent adverse effect was insomnia in 21.9% of patients. Of the 32 patients, 23 continued with the treatment during the 3-month follow-up period. CONCLUSIONS. In patients with type I narcolepsy who do not respond to or do not tolerate the available treatments, pitolisant can improve their clinical situation and reduce their medication consumption. Studies with a higher level of evidence are needed to confirm these results. Viguera Editores (Evidenze Group) 2022-10-01 /pmc/articles/PMC10280761/ /pubmed/36169322 http://dx.doi.org/10.33588/rn.7507.2022090 Text en Copyright: © Revista de Neurología https://creativecommons.org/licenses/by-nc-nd/4.0/Revista de Neurología trabaja bajo una licencia Creative Commons |
spellingShingle | Original del Río-Villegas, Rafael Martínez-Orozco, Francisco J. Tomás, Odile Romero-Santo Cortés, María Yébenes Gómez-Barrera, Manuel Gaig-Ventura, Carles Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
title | Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
title_full | Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
title_fullStr | Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
title_full_unstemmed | Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
title_short | Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
title_sort | estudio wake de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280761/ https://www.ncbi.nlm.nih.gov/pubmed/36169322 http://dx.doi.org/10.33588/rn.7507.2022090 |
work_keys_str_mv | AT delriovillegasrafael estudiowakedevidarealenpacientesconnarcolepsiaconcataplejiatratadosconpitolisantnorespondedoresatratamientosprevios AT martinezorozcofranciscoj estudiowakedevidarealenpacientesconnarcolepsiaconcataplejiatratadosconpitolisantnorespondedoresatratamientosprevios AT tomasodileromerosanto estudiowakedevidarealenpacientesconnarcolepsiaconcataplejiatratadosconpitolisantnorespondedoresatratamientosprevios AT cortesmariayebenes estudiowakedevidarealenpacientesconnarcolepsiaconcataplejiatratadosconpitolisantnorespondedoresatratamientosprevios AT gomezbarreramanuel estudiowakedevidarealenpacientesconnarcolepsiaconcataplejiatratadosconpitolisantnorespondedoresatratamientosprevios AT gaigventuracarles estudiowakedevidarealenpacientesconnarcolepsiaconcataplejiatratadosconpitolisantnorespondedoresatratamientosprevios |